Intranasal Powder:
Faster Absorption. Higher Impact. Lifesaving Potential.
Pioneering powder-based intranasal therapies that deliver rapid, superior absorption for acute, life-threatening emergencies—backed by clinical evidence and a scalable, proprietary platform.
The Nasax® Platform: Clinically Validated, Scalable, Lifesaving
The Nasax® proprietary powder formulation for intranasal delivery is comprised of uniform-sized spherical API and a carrier approved for inhalation. The technology enables a rapid and precise delivery of the drug to the bloodstream and brain. Stability data demonstrate the potential for a longer shelf life and other advantages versus liquid formulations.
Faster Onset
Higher Bioavailability
Stable & Portable
Liquid Formulation
Powder Formulation
Our Lead Candidate
Epinephrine for anaphylaxis
NS002 treats anaphylaxis, providing superior absorption and rapid therapeutic onset. Phase 2 data show higher early exposure and predictable pharmacokinetics versus traditional injectables.